Stockscreener 앱 받기
3.98
0.25%
0.010
Eupraxia Pharmaceuticals Inc 주식(EPRX)의 최신 뉴스
(EPRX) Advanced Equity Analysis (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Strengthens Governance with Board Elections and Strategic Approvals - TipRanks
Why Broadcom Stock Blew Past the Market on Monday - The Globe and Mail
Why Meta Platforms Stock Soared on AI News Today - The Globe and Mail
Hogs Close Mixed on Monday - The Globe and Mail
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders - GlobeNewswire
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders - GlobeNewswire Inc.
Stocks in play: Ares Strategic Mining Inc - The Globe and Mail
Should You Buy Paylocity Stock Despite its 7% Dip in 3 Months? - The Globe and Mail
Most Anticipated Earnings this Week – Week of June 2, 2025 - The Globe and Mail
E3 Lithium Provides Progress Update for the Demonstration Facility - The Globe and Mail
(EPRX.WT.A) Stock Market Analysis - news.stocktradersdaily.com
(EPRX) Investment Strategy and Analysis (EPRX:CA) - news.stocktradersdaily.com
(EPRX.WT.A) Equity Market Report - news.stocktradersdaily.com
2 Top Stocks to Buy With Less Than $100 - The Globe and Mail
(EPRX) Market Performance Analysis (EPRX:CA) - news.stocktradersdaily.com
Definity Financial Corporation Announces Increased Size of Previously Announced Private Placements of Common Shares to $385 million - The Globe and Mail
Should You Buy High-Yield Enterprise Products Partners While It's Below $36? - The Globe and Mail
(EPRX.WT.A) Technical Patterns and Signals - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Trading Down 0% – Here’s What Happened - Defense World
Travel + Leisure Up 10% in a Month: Hold Steady or Lock in Gains? - The Globe and Mail
(EPRX) Strategic Market Analysis (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Inc - Stockhouse
(EPRX) Long Term Investment Analysis (EPRX:CA) - news.stocktradersdaily.com
Long Term Trading Analysis for (EPRX.WT.A) - news.stocktradersdaily.com
“Bear-Pit Session” Highlights Peterson Capital’s Canada Growth Conference in Montreal - The Globe and Mail
11,613 Shares in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Acquired by Raymond James Financial Inc. - Defense World
(EPRX.WT.A) Comprehensive Trading Strategy Report - news.stocktradersdaily.com
Trading (EPRX) With Integrated Risk Controls (EPRX:CA) - news.stocktradersdaily.com
Raymond James Sticks to Its Buy Rating for Eupraxia Pharmaceuticals (EPRX) - The Globe and Mail
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results - The Globe and Mail
Eupraxia Pharmaceuticals (EPRX) to Release Earnings on Wednesday - Defense World
(EPRX.WT.A) Trading Strategy and Analysis - news.stocktradersdaily.com
Eupraxia Pharmaceuticals to Host Virtual KOL Event to - GlobeNewswire
DDOG Q1 Earnings Call: Growth in Large Deals, AI Adoption, and Platform Expansion Drive Outlook - The Globe and Mail
Eupraxia Pharmaceuticals to Host Virtual Event on EoE Treatment Study - TipRanks
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 - GlobeNewswire
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results - Stock Titan
Eupraxia Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
(EPRX.WT.A) Strategic Equity Report - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results - ADVFN
Eupraxia Pharmaceuticals Inc. - MENAFN.com
Stocks In Play: Eupraxia Pharmaceuticals Inc. By Baystreet.ca - Investing.com Canada
Aptose Biosciences Inc. - Baystreet.ca
Stocks in play: Eupraxia Pharmaceuticals Inc. - The Globe and Mail
Eupraxia Pharmaceuticals Reports Positive Nine-Month Outcomes in EoE Trial - TipRanks
Eupraxia Pharma Reports Positive 9-month Data From RESOLVE Phase 1b/2a Study - Nasdaq
Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI - GlobeNewswire
When the Price of (EPRX) Talks, People Listen (EPRX:CA) - news.stocktradersdaily.com
Breakthrough: New EoE Drug Shows Unprecedented 9-Month DurationCould Transform Treatment Landscape - Stock Titan
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024 - Seeking Alpha
(EPRX.WT.A) Proactive Strategies (EPRX.WT.A:CA) - news.stocktradersdaily.com
(EPRX.WT.A) Dynamic Trading Report - news.stocktradersdaily.com
How the (EPRX) price action is used to our Advantage (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals to Showcase Clinical Advances at April and May Conferences - MSN
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May - The Manila Times
Eupraxia Pharmaceuticals Inc. to Present at Multiple Upcoming Investor and Scientific Conferences in April and May 2025 - Nasdaq
(EPRX) Trading Signals (EPRX:CA) - news.stocktradersdaily.com
(EPRX.WT.A) Optimized Trading Opportunities - news.stocktradersdaily.com
1.30%
3.35%
자본화:
|
볼륨(24시간):